This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

REYVOW™ (lasmiditan): Half-Life

The elimination half-life of Reyvow (lasmiditan) is 5.7 hours.

Additional PK Characteristics

Lasmiditan was eliminated with a geometric mean t½ value of approximately 5.7 hours.1

No accumulation of lasmiditan was observed with daily dosing.1

Lasmiditan is primarily metabolized by ketone reduction to the alcohol S-M8, with very little parent drug (approximately 3%) excreted unchanged in urine.1

Renal excretion is a minor route of lasmiditan clearance.1

Enclosed Prescribing Information

REYVOW™ (lasmiditan) tablets for oral use, Lilly


1. Reyvow [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.


PK = pharmacokinetics

t1/2 = elimination half-life

Date of Last Review: November 20, 2018

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 8pm ET

Or you can

Ask us a question Chat with us

Submit a Request

Visit Us @LillyMedical